Latest News and Press Releases

ROCKVILLE, Md., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...

Second quarter 2022 total revenues of $170.1 million, a 20% increase compared to second quarter 2021Second quarter 2022 GAAP operating earnings of $11.3 million; second quarter 2022 non-GAAP operating...

ROCKVILLE, Md., July 25, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...

ROCKVILLE, Md., June 02, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...

First quarter 2022 total revenues of $152.5 million, a 16% increase compared to first quarter 2021First quarter 2022 net earnings and diluted earnings per share (GAAP) were $25.6 million and $0.43,...

ROCKVILLE, Md., May 02, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...

First novel, nonstimulant option for adults with ADHD in 20 yearsADHD affects an estimated 10 million adults in the U.S. ROCKVILLE, Md., April 29, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals,...

Annual Report on Form 10-K filed on April 13, 2022Reiterates full year 2022 financial guidance provided on February 28, 2022 and reiterated on April 4, 2022 ROCKVILLE, Md., April 13, 2022 (GLOBE...

Annual Report on Form 10-K for fiscal year ended December 31, 2021 to be filed in the near termReiterates full year 2022 financial guidance provided on February 28, 2022 ROCKVILLE, Md., April 04,...

ROCKVILLE, Md., March 17, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...